Psoriasis Drug Market
Psoriasis Drug Market Size, Share & Trends Analysis Report, By Drug Class (Biologics, Small Molecules, Topical Therapies, Systemic Non-Biologics), By Disease Type (Plaque Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, Psoriatic Arthritis), By Severity Level (Mild Psoriasis, Moderate Psoriasis, Severe Psoriasis), By End-User (Hospitals, Dermatology Clinics, Homecare Settings), Forecast Period (2026-2035)
Industry Overview
Psoriasis drug market size was valued at $27.50 billion in 2025 and is projected to reach $66.90 billion by 2035, growing at a CAGR of 10.37% between 2026 and 2035. The market consists of pharmaceutical treatments used to manage chronic autoimmune skin conditions characterized by inflammation and rapid skin cell turnover. A key driver supporting market growth is the increasing prevalence of psoriasis and related autoimmune disorders globally. According to the World Health Organization, psoriasis affects over 125 million people worldwide, highlighting a large and growing patient pool. Additionally, increasing healthcare expenditure and improved access to biologic therapies are accelerating treatment adoption. The market is witnessing a shift toward targeted biologics such as IL-17 and IL-23 inhibitors, which provide enhanced treatment outcomes and reduced relapse rates. Psoriasis drugs are extensively used across hospitals, dermatology clinics, and homecare settings, supporting long-term disease management and improving patient quality of life.
Market Dynamics
Rising Prevalence of Autoimmune Disorders Driving Market Growth
The increasing prevalence of autoimmune diseases is a major factor driving the psoriasis drug market. According to the World Health Organization, chronic inflammatory diseases are rising globally due to lifestyle changes and environmental factors. This has led to increased demand for long-term therapeutic solutions for psoriasis and related conditions. Additionally, according to the Organisation for Economic Co-operation and Development, healthcare spending across major economies continues to rise, improving access to advanced biologic therapies. Pharmaceutical companies are focusing on expanding their immunology portfolios and investing in targeted therapies between 2023 and 2026 to enhance treatment outcomes. These strategies are driving the adoption of biologics and small molecule drugs across hospitals and dermatology clinics.
High Treatment Cost and Therapy Complexity Limiting Market Growth
Despite strong growth, the psoriasis drug market faces challenges related to high treatment costs and therapy complexity. Biologic drugs require significant investment in research, development, and manufacturing, increasing overall treatment costs. According to the U.S. Food and Drug Administration, regulatory requirements for biologics add to development timelines and expenses. Additionally, long-term therapy adherence and potential side effects pose challenges for patients. To address these issues, companies are focusing on developing biosimilars, cost-effective generics, and improved drug delivery systems. These strategies aim to enhance accessibility and affordability while maintaining treatment effectiveness.
Market Segmentation
- Based on the drug class, the market is segmented into biologics, small molecules, topical therapies, and systemic non-biologics.
- Based on the disease type, the market is segmented into plaque psoriasis, guttate psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, and Psoriatic arthritis.
- Based on the severity level, the market is segmented into mild psoriasis, moderate psoriasis, and severe psoriasis.
- Based on the end-user, the market is segmented into hospitals, dermatology clinics, and homecare settings.
Biologics Segment Leads the Market
The biologics segment holds a dominant position in the psoriasis drug market due to its high effectiveness in treating moderate-to-severe psoriasis. These therapies target specific immune pathways such as TNF-alpha, IL-17, and IL-23, improving clinical outcomes and reducing disease severity. Increasing adoption of biologics across healthcare systems and continuous investments in immunology research between 2022 and 2026 are driving segment growth.
Small Molecules Segment to Record Strong Growth
The small molecules segment is expected to witness strong growth due to increasing demand for oral therapies and improved patient convenience. These drugs offer significant cost advantages and ease of administration compared to biologics, as they eliminate the need for injections or infusion-based delivery. Additionally, small molecules such as PDE4 inhibitors and JAK inhibitors are gaining traction due to their targeted mechanism of action and favourable safety profiles in long-term treatment. Rising adoption in emerging markets, where affordability and accessibility are critical factors, is further supporting segment expansion. Continuous innovation in oral immunomodulators and ongoing clinical research are enhancing treatment efficacy and broadening therapeutic applications, thereby accelerating the growth of the small molecules segment in the psoriasis drug market.
Regional Outlook
The global psoriasis drug market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the psoriasis drug market due to high healthcare expenditure and advanced pharmaceutical infrastructure. According to the U.S. Food and Drug Administration, continuous approvals of biologics and specialty drugs are supporting market growth.
China to Record Strong Growth
China is expected to witness strong growth due to increasing healthcare investments and pharmaceutical manufacturing expansion. According to the International Trade Centre, China’s growing pharmaceutical exports are supporting the availability of advanced therapies.
Competitive Landscape
The psoriasis drug market is highly competitive, characterized by strong innovation in biologics and targeted therapies. Leading companies such as AbbVie Inc., Johnson & Johnson, Novartis AG, Amgen Inc., and Eli Lilly and Company are focusing on expanding their product portfolios and strengthening global market presence.
Recent Developments
- In March 2026, AbbVie Inc. presented positive clinical data at the American Academy of Dermatology (AAD) Annual Meeting demonstrating improved quality-of-life outcomes at 16 weeks for patients treated with Skyrizi (risankizumab) in genital and scalp psoriasis. The update followed the U.S. Food and Drug Administration approval of supplemental labeling for high-impact body regions, strengthening the company’s position in targeted biologic therapies.
- In March 2026, Arcutis Biotherapeutics, Inc. reported positive long-term safety and efficacy data for its topical therapy Zoryve (roflumilast), highlighting its potential as a non-steroidal treatment option for localized plaque psoriasis. The development strengthens its position in topical therapies by offering an alternative to corticosteroids with reduced long-term side effects.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualised market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global psoriasis drug market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Global Psoriasis Drug Market Sales Analysis – Drug Class | Disease Type |
Severity Level | End-User ($ Million)
• Psoriasis Drug Market Sales Performance of Top Countries
1.1 Research Methodology
• Primary Research Approach
• Secondary Research Approach
1.2 Market Snapshot
2. Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Psoriasis Drug Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Psoriasis Drug Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
3. Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Psoriasis Drug Market: Impact
Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Psoriasis Drug Market: Impact
Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Psoriasis Drug Market: Impact
Analysis
4. Competitive Landscape
4.1 Competitive Dashboard – Psoriasis Drug Market Revenue and
Share by Manufacturers
• Psoriasis Drug Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 AbbVie Inc.
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Johnson & Johnson
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Novartis AG
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Amgen Inc.
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Eli Lilly and Company
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
5. Global Psoriasis Drug Market Sales Analysis by Drug Class
($ Million)
5.1 Biologics
5.2 Small Molecules
5.3 Topical Therapies
5.4 Systemic Non-Biologics
6. Global Psoriasis Drug Market Sales Analysis by Disease
Type ($ Million)
6.1 Plaque Psoriasis
6.2 Guttate Psoriasis
6.3 Pustular Psoriasis
6.4 Erythrodermic Psoriasis
6.5 Psoriatic Arthritis
7. Global Psoriasis Drug Market Sales Analysis by Severity
Level ($ Million)
7.1 Mild Psoriasis
7.2 Moderate Psoriasis
7.3 Severe Psoriasis
8. Global Psoriasis Drug Market Sales Analysis by End-User ($
Million)
8.1 Hospitals
8.2 Dermatology Clinics
8.3 Homecare Settings
9. Regional Analysis
9.1 North American Psoriasis Drug Market Sales Analysis –
Drug Class | Disease Type | Severity Level | End-User ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Psoriasis Drug Market Sales Analysis – Drug
Class | Disease Type | Severity Level | End-User ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Psoriasis Drug Market Sales Analysis – Drug
Class | Disease Type | Severity Level | End-User ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Psoriasis Drug Market Sales Analysis –
Drug Class | Disease Type | Severity Level | End-User ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
10. Company Profiles
10.1 Almirall, S.A.
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 Arcutis Biotherapeutics, Inc.
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 AstraZeneca PLC
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 Bausch Health Companies Inc.
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Biogen Inc.
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 Boehringer Ingelheim International GmbH
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 Bristol Myers Squibb
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 Dermavant Sciences, Inc.
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Dr. Reddy's Laboratories Ltd.
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 Galderma S.A.
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 Glenmark Pharmaceuticals Ltd.
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Kyowa Kirin Co., Ltd.
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 Leo Pharma A/S
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Organon & Co.
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Pfizer Inc.
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Sandoz Group AG
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 Sun Pharmaceutical Industries Ltd.
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 Takeda Pharmaceutical Company Limited
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Teva Pharmaceutical Industries Ltd.
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 UCB S.A.
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1. Global Psoriasis Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Biologics Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Small Molecules Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Topical Therapies Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Systemic Non-Biologics Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Psoriasis Drug Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
7. Global Plaque Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Guttate Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Pustular Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Erythrodermic Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Psoriatic Arthritis Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Psoriasis Drug Market Research and Analysis by Severity Level, 2025–2035 ($ Million)
13. Global Mild Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
14. Global Moderate Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Severe Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Psoriasis Drug Market Research and Analysis by End-User, 2025–2035 ($ Million)
17. Global Psoriasis Drug Market Research and Analysis by Region for Hospitals, 2025–2035 ($ Million)
18. Global Psoriasis Drug Market Research and Analysis by Region for Dermatology Clinics, 2025–2035 ($ Million)
19. Global Psoriasis Drug Market Research and Analysis by Region for Homecare Settings, 2025–2035 ($ Million)
20. Global Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
21. North America Psoriasis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
22. Europe Psoriasis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
23. Asia-Pacific Psoriasis Drug Market Research and Analysis by Country, 2025–2035 ($ Million)
24. Rest of the World Psoriasis Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
1. Global Psoriasis Drug Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global Biologics Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
3. Global Small Molecules Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
4. Global Topical Therapies Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
5. Global Systemic Non-Biologics Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
6. Global Psoriasis Drug Market Share by Disease Type, 2025 Vs 2035 (%)
7. Global Plaque Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
8. Global Guttate Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
9. Global Pustular Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
10. Global Erythrodermic Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
11. Global Psoriatic Arthritis Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
12. Global Psoriasis Drug Market Share by Severity Level, 2025 Vs 2035 (%)
13. Global Mild Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
14. Global Moderate Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
15. Global Severe Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
16. Global Psoriasis Drug Market Share by End-User, 2025 Vs 2035 (%)
17. Global Hospitals Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
18. Global Dermatology Clinics Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
19. Global Homecare Settings Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
20. Global Psoriasis Drug Market Share by Region, 2025 Vs 2035 (%)
21. US Psoriasis Drug Market Size, 2025–2035 ($ Million)
22. Canada Psoriasis Drug Market Size, 2025–2035 ($ Million)
23. UK Psoriasis Drug Market Size, 2025–2035 ($ Million)
24. France Psoriasis Drug Market Size, 2025–2035 ($ Million)
25. Germany Psoriasis Drug Market Size, 2025–2035 ($ Million)
26. Italy Psoriasis Drug Market Size, 2025–2035 ($ Million)
27. Spain Psoriasis Drug Market Size, 2025–2035 ($ Million)
28. Russia Psoriasis Drug Market Size, 2025–2035 ($ Million)
29. India Psoriasis Drug Market Size, 2025–2035 ($ Million)
30. China Psoriasis Drug Market Size, 2025–2035 ($ Million)
31. Japan Psoriasis Drug Market Size, 2025–2035 ($ Million)
32. South Korea Psoriasis Drug Market Size, 2025–2035 ($ Million)
33. Australia & New Zealand Psoriasis Drug Market Size, 2025–2035 ($ Million)
34. ASEAN Psoriasis Drug Market Size, 2025–2035 ($ Million)
35. Rest of Asia-Pacific Psoriasis Drug Market Size, 2025–2035 ($ Million)
36. Latin America Psoriasis Drug Market Size, 2025–2035 ($ Million)
37. Middle East & Africa Psoriasis Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
